JP2011503166A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503166A5
JP2011503166A5 JP2010533666A JP2010533666A JP2011503166A5 JP 2011503166 A5 JP2011503166 A5 JP 2011503166A5 JP 2010533666 A JP2010533666 A JP 2010533666A JP 2010533666 A JP2010533666 A JP 2010533666A JP 2011503166 A5 JP2011503166 A5 JP 2011503166A5
Authority
JP
Japan
Prior art keywords
carbonyl
oxo
oxopiperazin
fluoro
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010533666A
Other languages
English (en)
Japanese (ja)
Other versions
JP5758630B2 (ja
JP2011503166A (ja
Filing date
Publication date
Priority claimed from GB0722401A external-priority patent/GB0722401D0/en
Priority claimed from GB0816707A external-priority patent/GB0816707D0/en
Application filed filed Critical
Priority claimed from PCT/GB2008/051063 external-priority patent/WO2009063244A1/en
Publication of JP2011503166A publication Critical patent/JP2011503166A/ja
Publication of JP2011503166A5 publication Critical patent/JP2011503166A5/ja
Application granted granted Critical
Publication of JP5758630B2 publication Critical patent/JP5758630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010533666A 2007-11-15 2008-11-14 Parp阻害剤としてのピリダジノン誘導体 Active JP5758630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0722401.7 2007-11-15
GB0722401A GB0722401D0 (en) 2007-11-15 2007-11-15 Therapeutic compounds
GB0816707.4 2008-09-12
GB0816707A GB0816707D0 (en) 2008-09-12 2008-09-12 Therapeutic compounds
PCT/GB2008/051063 WO2009063244A1 (en) 2007-11-15 2008-11-14 Pyridazinone derivatives as parp inhibitors

Publications (3)

Publication Number Publication Date
JP2011503166A JP2011503166A (ja) 2011-01-27
JP2011503166A5 true JP2011503166A5 (enExample) 2011-12-15
JP5758630B2 JP5758630B2 (ja) 2015-08-05

Family

ID=40427149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533666A Active JP5758630B2 (ja) 2007-11-15 2008-11-14 Parp阻害剤としてのピリダジノン誘導体

Country Status (14)

Country Link
US (1) US8268827B2 (enExample)
EP (1) EP2220073B1 (enExample)
JP (1) JP5758630B2 (enExample)
KR (1) KR101641596B1 (enExample)
CN (1) CN101855221B (enExample)
AU (1) AU2008322676B9 (enExample)
CA (1) CA2704714C (enExample)
ES (1) ES2524787T3 (enExample)
IL (1) IL205142A (enExample)
MX (1) MX2010005070A (enExample)
NZ (1) NZ585395A (enExample)
RU (1) RU2490265C2 (enExample)
WO (1) WO2009063244A1 (enExample)
ZA (1) ZA201002466B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369186B (zh) * 2009-04-02 2014-07-09 默克专利有限公司 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
EP2686305B1 (en) * 2011-03-14 2020-09-16 Impact Therapeutics, Inc. Quinazolinediones and their use
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
CN103703004B (zh) 2011-12-31 2016-06-29 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
AU2013209394A1 (en) 2012-01-20 2014-08-28 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
HRP20200064T1 (hr) * 2015-06-09 2020-04-03 Abbvie Inc. Modulatori nuklearnih receptora (ror) namijenjeni liječenju upalnih i autoimunih bolesti
KR102088157B1 (ko) * 2015-09-02 2020-03-12 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서 사용하기 위한 피리디논 디카복스아미드
WO2017059080A1 (en) 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
KR102030016B1 (ko) 2016-09-05 2019-10-08 충남대학교산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
CN108383837B (zh) * 2018-02-09 2020-08-11 福建医科大学 一种氨基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用
ES2949538T3 (es) * 2018-04-30 2023-09-29 Ribon Therapeutics Inc Piridazinonas como inhibidores de PARP7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
KR102017115B1 (ko) 2018-05-15 2019-09-02 충남대학교산학협력단 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
CN110818908B (zh) * 2019-08-29 2021-12-17 杭州市富阳区浙工大银湖创新创业研究院 一种用于检测氧化气体的金属有机骨架材料的制备方法
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN114929673B (zh) 2019-10-30 2025-06-06 多临生物株式会社 异喹啉酮衍生物、其制备方法和其用途
IL292432A (en) * 2019-10-30 2022-06-01 Ribon Therapeutics Inc Pyridazinones as parp7 inhibitors
JP7626783B2 (ja) 2020-04-21 2025-02-07 アイディーエンス カンパニー リミテッド フタラジノン誘導体及びその中間体を調製するプロセス
JP2023537550A (ja) 2020-04-21 2023-09-04 アイディーエンス カンパニー リミテッド フタラジノン化合物の結晶形
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2022188889A1 (zh) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2024511208A (ja) 2021-03-27 2024-03-12 ティーアールエックス バイオサイエンシズ リミテッド 治療薬のバイオアベイラビリティを改善した組成物
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药(上海)有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
TW202321224A (zh) * 2021-07-29 2023-06-01 大陸商上海齊魯製藥研究中心有限公司 新型parp7抑制劑及其應用
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
TWI857377B (zh) * 2021-10-28 2024-10-01 美商基利科學股份有限公司 嗒-3(2h)-酮衍生物
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
JP2025509680A (ja) * 2022-03-14 2025-04-11 ティーアールエックス バイオサイエンシズ リミテッド 治療薬のバイオアベイラビリティを改善した組成物およびその使用
CA3220874A1 (en) * 2022-04-01 2023-10-05 Bing Li Parp7 inhibitor and use thereof
WO2024073133A1 (en) * 2022-09-30 2024-04-04 Azkarra Therapeutics, Inc. Pyridazin-3(2h)-one and pyridin-2(1h)-one parp inhibitor compounds
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025087383A1 (zh) * 2023-10-26 2025-05-01 深圳众格生物科技有限公司 作为parp7抑制剂的化合物
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CN1136197C (zh) 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
CN100400518C (zh) 2000-10-30 2008-07-09 库多斯药物有限公司 2,3-二氮杂萘酮衍生物
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
EP1501822B1 (en) 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
MXPA05010081A (es) 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
MXPA06009701A (es) 2004-02-26 2007-03-26 Inotek Pharmaceuticals Corp Derivados de isoquinolina y metodos de uso de los mismos.
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005100323A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
JP2008510783A (ja) 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド 4−ヘテロアリールメチル置換フタラジノン誘導体
NZ565190A (en) 2005-07-21 2010-02-26 Hoffmann La Roche Pyridazinone derivatives as thyroid hormone receptor agonists
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
MY165570A (en) * 2006-12-28 2018-04-05 Abbvie Inc Inhibitors of poly (adp-ribose) polymerase
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives

Similar Documents

Publication Publication Date Title
JP2011503166A5 (enExample)
RU2010123874A (ru) Пиридазиноновые производные в качестве ингибиторов parp
RU2396269C2 (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2007510689A5 (enExample)
RU2008141761A (ru) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
JP2008513514A5 (enExample)
JP2019077725A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
RU2016124178A (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
JP2018530591A5 (enExample)
JP2020515575A5 (enExample)
RU2010137300A (ru) Модуляторы бета-амилоида
JP2016523911A5 (enExample)
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
JP2014062093A5 (enExample)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2017502049A5 (enExample)
IL277579B (en) Piperidinone derivatives as mdm2 inhibitors for cancer therapy
JP2011500806A5 (enExample)
RU2016141646A (ru) Ингибиторы trka киназы, основанные на них композиции и способы
JP2014517833A5 (enExample)
JP2007523182A5 (enExample)
JP2013533868A5 (enExample)